Aptorum Group Limited Announces Appointment of Head of R&D and Chief Operating Officer
2019年4月1日 - 10:30PM
ビジネスワイヤ(英語)
Aptorum Group Limited (Nasdaq: APM) (“Aptorum”) announced today,
the appointment of Dr. Thomas Wai-yip Lee as Head of Research and
Development (“Head of R&D”) and Dr. Angel Siu-yan Ng as Chief
Operating Officer (“COO”) of Aptorum, effective on April 1,
2019.
Dr. Thomas Lee joined Aptorum in January 2018 as the Chief
Executive Officer and Chief Scientific Officer of Aptorum
Therapeutics Limited, a wholly-owned subsidiary of Aptorum. Before
joining Aptorum, Dr. Lee was an Assistant Professor at the School
of Pharmacy at The Chinese University of Hong Kong. His key area of
research involves drug delivery with specialties on formulation
development of poorly soluble compounds, oral delivery,
nanotechnology, and similar fields. Prior to academia, Dr. Lee
accumulated big-pharma experience from spending a decade at two
global pharmaceutical companies in the U.S.
Dr. Angel Ng joined Aptorum in September 2017 as Chief Operating
Officer of Aptorum Therapeutics Limited. Dr. Ng leads Aptorum and
its subsidiary companies’ operations and business strategies. Dr.
Ng has extensive experience in project management with Innovation
and Technology government funds and academic institutions. She also
worked on technology transfer and commercialization for research
and development projects.
At the same time, Dr. Keith Kwei-hang Chan, Chief Scientific
Officer (“CSO”) of Aptorum, will transition to serve as a key
member of our newly formed Scientific Advisory Board, effective on
April 1, 2019.
“I am pleased to announce the expansion of our management team.
Dr. Lee has gained solid research and development experience from
academia and big pharma, and Dr. Ng has extensive experience in
operations and project management. Their expertise and experience
will be most invaluable in advancing Aptorum’s pipeline.” said Mr.
Ian Huen, the Founder, Executive Director and Chief Executive
Officer of Aptorum. “We also thank Dr. Chan for his significant
contributions to Aptorum during his term as CSO, and for his
continuous support to Aptorum’s development by serving on the
Scientific Advisory Board.”
About Aptorum Group Limited
We are a Hong Kong based pharmaceutical company currently in the
preclinical stage, dedicated to developing and commercializing a
broad range of therapeutic and diagnostic technologies to tackle
unmet medical needs. We are pursuing therapeutic and diagnostic
projects in neurology, infectious diseases, gastroenterology,
oncology and other disease areas. We also have projects focused on
non-therapeutic area such as surgical robotics as well as the
operations of our medical clinic in Hong Kong, Talem Medical, with
the initial focus on treatment of chronic diseases resulting from
modern sedentary lifestyles and aging population.
For more information about the Company, please visit
www.aptorumgroup.com.
Forward-Looking Statements
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
has based these forward-looking statements largely on its current
expectations and projections about future events and trends that it
believes may affect its business, financial condition and results
of operations. These forward-looking statements speak only as of
the date of this press release and are subject to a number of
risks, uncertainties and assumptions including, without limitation,
risks related to its announced management and organizational
changes, the continued service and availability of key personnel,
its ability to expand its product assortments by offering
additional products for additional consumer segments, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum’s
Prospectus (File No. 333-227198) filed with the U.S. Securities and
Exchange Commission (the “SEC”) on December 4, 2018 and other
filings that Aptorum may make with the SEC in the future. Aptorum
assumes no obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190401005315/en/
Investor relations:Tel: +852 2117 6611Email:
investor.relations@aptorumgroup.comMedia:Tel: + 852 2117 6611Email:
info@aptorumgroup.com
Aptorum (NASDAQ:APM)
過去 株価チャート
から 3 2024 まで 4 2024
Aptorum (NASDAQ:APM)
過去 株価チャート
から 4 2023 まで 4 2024